论文部分内容阅读
目的:探讨磁导向甲氨蝶呤缓释药物(FM-MTX)的药学参数。方法:采用分光光谱法、高效液相色谱法、原子吸收光谱法检测磁导向甲氨蝶呤缓释药物的含量及组成,并对FM-MTX的比重、沸点、粒径和稳定性进行检测。结果:HPLC法检测FM-MTX中MTX药物含量为260mg/L。Fe3O4平均含量为66.29mg/L。FM-MTX粒度分布均匀,粒径为0.4～1.0μm,占88.61%。FM-MTX药物含量稳定,放置6个月,含量未见明显变化。结论:应用化学交联法研制的磁导向甲氨蝶呤缓释药物基本可满足血管内给药的质控要求
Objective: To investigate the pharmacological parameters of magnetic-guided methotrexate sustained-release drug (FM-MTX). Methods: The content and composition of magnetotactic methotrexate sustained-release drug were detected by spectrophotometry, high performance liquid chromatography and atomic absorption spectrometry. The specific gravity, boiling point, particle size and stability of FM-MTX were detected. Results: The content of MTX in FM-MTX by HPLC was 260mg / L. The average content of Fe3O4 was 66.29mg / L. FM-MTX particle size distribution, particle size of 0.4 ~ 1.0μm, accounting for 88.61%. FM-MTX drug content was stable, place for 6 months, no significant change in content. Conclusion: The magnetic guide methotrexate sustained release drug developed by chemical cross-linking method can basically meet the quality control requirements of intravascular administration